Published in Vaccine Weekly, July 24th, 2002
The decision was based on the unanimous positive opinion adopted by the Committee for Proprietary Medicinal Products on March 21, 2002.
This license allows millions of hepatitis C patients in the European Union to access a treatment with increased efficacy, even for those with the more difficult-to-treat forms of the disease.
"Today is a very important day for Roche and for Pegasys," said William M. Burns, head of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly